Clinically relevant doses of FLT3-kinase inhibitors quizartinib and midostaurin do not impair T-cell reactivity and function.

2.50
Hdl Handle:
http://hdl.handle.net/10033/325037
Title:
Clinically relevant doses of FLT3-kinase inhibitors quizartinib and midostaurin do not impair T-cell reactivity and function.
Authors:
Wolleschak, Denise; Mack, Thomas S; Perner, Florian; Frey, Stephanie; Schnöder, Tina M; Wagner, Marie-Christine; Höding, Christine; Pils, Marina C; Parkner, Andreas; Kliche, Stefanie; Schraven, Burkhart; Hebel, Katrin; Brunner-Weinzierl, Monika; Ranjan, Satish; Isermann, Berend; Lipka, Daniel B; Fischer, Thomas; Heidel, Florian H
Citation:
Clinically relevant doses of FLT3-kinase inhibitors quizartinib and midostaurin do not impair T-cell reactivity and function. 2014, 99 (6):e90-3 Haematologica
Journal:
Haematologica
Issue Date:
Jun-2014
URI:
http://hdl.handle.net/10033/325037
DOI:
10.3324/haematol.2014.104331
PubMed ID:
24633870
Type:
article
Language:
en
ISSN:
1592-8721
Appears in Collections:
publications of the department of immune control (IMMK)

Full metadata record

DC FieldValue Language
dc.contributor.authorWolleschak, Deniseen
dc.contributor.authorMack, Thomas Sen
dc.contributor.authorPerner, Florianen
dc.contributor.authorFrey, Stephanieen
dc.contributor.authorSchnöder, Tina Men
dc.contributor.authorWagner, Marie-Christineen
dc.contributor.authorHöding, Christineen
dc.contributor.authorPils, Marina Cen
dc.contributor.authorParkner, Andreasen
dc.contributor.authorKliche, Stefanieen
dc.contributor.authorSchraven, Burkharten
dc.contributor.authorHebel, Katrinen
dc.contributor.authorBrunner-Weinzierl, Monikaen
dc.contributor.authorRanjan, Satishen
dc.contributor.authorIsermann, Berenden
dc.contributor.authorLipka, Daniel Ben
dc.contributor.authorFischer, Thomasen
dc.contributor.authorHeidel, Florian Hen
dc.date.accessioned2014-08-21T10:32:29Zen
dc.date.available2014-08-21T10:32:29Zen
dc.date.issued2014-06en
dc.identifier.citationClinically relevant doses of FLT3-kinase inhibitors quizartinib and midostaurin do not impair T-cell reactivity and function. 2014, 99 (6):e90-3 Haematologicaen
dc.identifier.issn1592-8721en
dc.identifier.pmid24633870en
dc.identifier.doi10.3324/haematol.2014.104331en
dc.identifier.urihttp://hdl.handle.net/10033/325037en
dc.language.isoenen
dc.rightsArchived with thanks to Haematologicaen
dc.titleClinically relevant doses of FLT3-kinase inhibitors quizartinib and midostaurin do not impair T-cell reactivity and function.en
dc.typearticleen
dc.identifier.journalHaematologicaen

Related articles on PubMed

This item is licensed under a Creative Commons License
Creative Commons
All Items in HZI are protected by copyright, with all rights reserved, unless otherwise indicated.